Miguel Ángel
Hernández Pérez
Professeur Assistant à Temps Partiel (Sciences de la Santé)
Publications (73) Publications de Miguel Ángel Hernández Pérez
2024
-
Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale
Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 10, Núm. 2
-
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study
Multiple Sclerosis and Related Disorders, Vol. 90
-
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023
Neurologia, Vol. 39, Núm. 2, pp. 196-208
-
Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis
Patient Preference and Adherence , Vol. 18, pp. 1163-1171
-
Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis
Multiple Sclerosis and Related Disorders, Vol. 91
-
XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (I)
Revista de neurologia, Vol. 79, Núm. 1, pp. 21-29
-
XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (II)
Revista de neurologia, Vol. 79, Núm. 2, pp. 51-66
2023
-
Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
Multiple Sclerosis Journal, Vol. 29, Núm. 14, pp. 1795-1807
-
Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193
-
Relapse, cognitive reserve, and their relationship with cognition in first episode schizophrenia: a 3-year follow-up study
European Neuropsychopharmacology, Vol. 67, pp. 53-65
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)
Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60
2022
-
Consensus on early detection of disease progression in patients with multiple sclerosis
Frontiers in Neurology, Vol. 13
-
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain
Neurologia, Vol. 37, Núm. 8, pp. 615-630
-
Expert-Agreed Practical Recommendations on the Use of Cladribine
Neurology and Therapy
-
What about the weekend effect? Impact of the day of admission on in-hospital mortality, length of stay and cost of hospitalization
Journal of Healthcare Quality Research, Vol. 37, Núm. 6, pp. 366-373
2021
-
Evaluation of Kappa Index as a Tool in the Diagnosis of Multiple Sclerosis: Implementation in Routine Screening Procedure
Frontiers in Neurology, Vol. 12
-
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
PLoS ONE, Vol. 16, Núm. 10 October
2020
-
Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study
Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 6, Núm. 3
-
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
Frontiers in Neurology, Vol. 11